---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/100000000770792.md"
description: "$Hims &amp; Hers Health(HIMS.US) | Canaccord maintains 𝐁𝐮𝐲 on 𝐇𝐢𝐦𝐬 &amp; 𝐇𝐞𝐫𝐬, 𝐫𝐚𝐢𝐬𝐞𝐬 𝐏𝐓 𝐭𝐨 $𝟒𝟎 𝐟𝐫𝐨𝐦 $𝟑𝟐Analyst highlights a solid start to branded weight loss drugs, constructive sales data, and sees Hims as one of Novo's most &#34;voluminous&#34; partners."
datetime: "2026-07-01T11:25:45.000Z"
locales:
  - [en](https://longbridge.com/en/topics/100000000770792.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/100000000770792.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/100000000770792.md)
author: "[Hardik Shah](https://longbridge.com/en/profiles/27423834.md)"
generator: "portal-rs"
---

# $Hims &amp; Hers Health(HIMS.US) | Canaccord maint…


### Related Stocks

- [HIMS.US](https://longbridge.com/en/quote/HIMS.US.md)
- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**